Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2014
|
| gptkbp:ATCCode |
L01XC19
|
| gptkbp:blackBoxWarning |
yes
|
| gptkbp:CASNumber |
1353551-71-3
|
| gptkbp:developer |
gptkb:Amgen
|
| gptkbp:drugClass |
gptkb:monoclonal_antibody
immunotherapy |
| gptkbp:firstBook |
yes
|
| gptkbp:form |
solution for infusion
|
| gptkbp:genericName |
gptkb:blinatumomab
|
| https://www.w3.org/2000/01/rdf-schema#label |
Blincyto
|
| gptkbp:indication |
leukemia
relapsed or refractory B-cell precursor acute lymphoblastic leukemia |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
CD19-directed
CD3-directed bispecific T-cell engager (BiTE) |
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
headache infections cytokine release syndrome neurological toxicity |
| gptkbp:target |
gptkb:CD3
gptkb:CD19 |
| gptkbp:UNII |
6Q1K1Y1F2E
|
| gptkbp:bfsParent |
gptkb:blinatumomab
|
| gptkbp:bfsLayer |
7
|